Researchers at the Instituto de Tecnologia Química e Biológica António Xavier of NOVA University of Lisbon are launching the BRIDGE project, aimed at unraveling the mechanisms by which aggressive breast cancer evades the immune system. This initiative seeks to identify biomarkers that can predict disease progression and inform personalized treatment strategies. By utilizing real patient samples, the team plans to translate laboratory findings into clinically applicable tools that can enhance the management of this challenging cancer subtype.

The significance of this research lies in its potential to address a critical gap in breast cancer care. With approximately 2.3 million women diagnosed globally in 2022, and a mortality rate of around 670,000, the need for reliable prognostic indicators is urgent. The BRIDGE project focuses on the tumor microenvironment, particularly the interactions between cancer cells and immune cells, which are crucial for tumor survival and progression. By investigating small molecules on cell surfaces that may facilitate immune evasion, the researchers aim to develop biomarkers that can indicate tumor behavior and response to therapies, thereby improving treatment outcomes.

The implications of this work extend beyond academic interest; it could significantly shift current paradigms in breast cancer research and treatment. By identifying and validating new biomarkers, the BRIDGE project aims to pave the way for more personalized therapies tailored to individual tumor characteristics, moving away from generalized treatment approaches. Funded by the iNOVA4Health Lighthouse Projects (LHP) 2025 program, the initiative is positioned to accelerate the transition from basic research to clinical application, ultimately enhancing patient care for those afflicted with aggressive breast cancer.

Source: sciencedaily.com